# Untitled situation

> Live situation record from CLSTR: https://clstr.news/situations/6b7f78a9-4c46-41f3-ac43-bcf544a154c3
> Updated: 2026-08-24T13:35:42.000Z. Sources: 2. Developments: 2.

## Timeline

### 2026-08-24: BioMarin Pharmaceutical to acquire Alesta Therapeutics

BioMarin Pharmaceutical will acquire Alesta Therapeutics for up to $490 million to secure ALE1, a potential first-of-its-kind oral treatment for the rare genetic disease hypophosphatasia.

2 sources. https://clstr.news/cluster/biomarin-pharmaceutical-to-acquire-alesta-therapeutics

### 2026-08-11: Mereo BioPharma and Sentynl Therapeutics partner on alvelestat licensing

Mereo BioPharma and Sentynl Therapeutics have signed a licensing deal for alvelestat, a potential first oral treatment for the rare lung disease AATD-LD.

2 sources. https://clstr.news/cluster/mereo-biopharma-and-sentynl-therapeutics-partner-on-alvelestat-licensing

---
Cite as: Untitled situation. CLSTR, https://clstr.news/situations/6b7f78a9-4c46-41f3-ac43-bcf544a154c3